The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Investment firms in Boston and New York could see the biggest gains from the sale of a Raleigh drugmaker. Raleigh pharma ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.

This is an audio transcript of the FT News Briefing podcast episode: ‘Big Pharma markets left in a ‘patent cliff’-hanger’ ...

U.S. appetite for U.K. companies is only intestifying in 2025; here, Law.com charts some of the highest profile deals in H1, ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

For the third time in four years, CNBC has ranked North Carolina as “America’s Top State for Business” in 2025.

Two art-market analysts find a bear market for auctions sales of art: For three seasons now, 50% of artworks resold at ...

US Foods Holding stock hit an all-time high Friday on a report that the firm was mulling an acquisition of Performance Food ...